Northwire Canada EditionSaturday, October 17, 2026
Northwire
⌕
GOLD 4181.10 +0.3% SILVER 57.30 +0.3% COPPER 6.57 +0.3% OIL 99.02 +1.1% PALLADIUM 1118.60 −0.9% GBU 0.095 +0.0% ATY 0.225 +4.7% GRDM 0.215 +0.0% PPM 0.300 +0.0% GZD 0.040 −11.1% CAN 0.060 +0.0% BGF 0.025 +0.0% MSV 0.570 +0.0% CCMM 0.485 +0.0% MON 0.385 −6.1% OMI 0.245 −2.0% BUFF 0.800 +2.6% FEO 0.630 −3.1% LIB 0.710 −1.4% NPR 0.620 +0.0% QZM 0.380 +0.0% GOLD 4181.10 +0.3% SILVER 57.30 +0.3% COPPER 6.57 +0.3% OIL 99.02 +1.1% PALLADIUM 1118.60 −0.9% GBU 0.095 +0.0% ATY 0.225 +4.7% GRDM 0.215 +0.0% PPM 0.300 +0.0% GZD 0.040 −11.1% CAN 0.060 +0.0% BGF 0.025 +0.0% MSV 0.570 +0.0% CCMM 0.485 +0.0% MON 0.385 −6.1% OMI 0.245 −2.0% BUFF 0.800 +2.6% FEO 0.630 −3.1% LIB 0.710 −1.4% NPR 0.620 +0.0% QZM 0.380 +0.0%
M&A / Property

Seegnal Expands Deployment of Seegnal's Prescription Intelligence Platform at Tel Aviv Sourasky Medical Center, a Leading Israeli Public Medical Center and Global Referral Center

SEGN · Price

Executive Summary

  • Seegnal Inc. announced an expanded deployment of its Prescription Intelligence Platform at Tel Aviv Sourasky Medical Center, covering the period Jan 1 2026 – Dec 31 2027 with an option to extend to 2031.
  • The platform will now support roughly 1,200 clinicians and 2,050 medical‑team members across multiple departments, reinforcing Seegnal’s role as a reference site for large public hospitals worldwide.
  • The expansion underscores measurable clinical and economic benefits (reduced medication‑related adverse events, lower hospitalizations, decreased alert fatigue) that Seegnal cites from peer‑reviewed research, positioning the partnership as a showcase for future global roll‑outs.

Key Details

  • Deployment Period: Jan 1 2026 – Dec 31 2027 (option to extend to Dec 31 2031).
  • Scope of Use: Approximately 1,200 clinicians and 2,050 medical‑team members will use the SaaS platform daily as part of routine workflows.
  • Clinical Coverage: Platform integrated across multiple inpatient and outpatient departments, delivering real‑time, patient‑specific medication decision support (lab results, comorbidities, renal function, polypharmacy, etc.).
  • Reference Site Role: Sourasky Medical Center serves as an active global reference site for other hospitals evaluating modern medication safety solutions.
  • Reported Benefits (per cited American Journal of Pharmacy Benefits article):
  • Reductions in medication‑related adverse events.
  • Fewer avoidable hospitalizations.
  • Decreased unnecessary medication utilization.
  • Improved prescribing efficiency and reduced alert fatigue.
  • Lower downstream costs and better alignment with value‑based care frameworks.
  • CEO Quote: “The expansion of our deployment reflects strong confidence in the clinical, operational, and economic value Seegnal delivers at scale.” – Elad Bibi‑Aviv, CEO.

Notable Quotes

“Sourasky Medical Center represents one of the most advanced clinical environments within public health systems worldwide.” – Elad Bibi‑Aviv, Chief Executive Officer, Seegnal.
“The expansion demonstrates that patient‑specific prescribing intelligence can improve safety and efficiency while supporting sustainable economics for large medical centers.” – Elad Bibi‑Aviv, CEO.

Read the original news release →

More from Seegnal Inc.